Johnson & Johnson (JNJ)

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

• Annual Report (10-K)

  A yearly overview of the business, its financial results, and the risks it faces.

  Filed on 2026-02-11

  View document

• Quarterly Report (10-Q)

  A snapshot of financial performance for the most recent three-month period.

  Filed on 2026-07-23

  View document

• Current Report (8-K)

  An announcement of a major event, such as a leadership change or big news.

  Filed on 2026-08-04

  View document

• 3d agoNEUTRAL
  J&J CEO Joaquin Duato on Obesity, Cancer and AI | The David Rubenstein Show

  Johnson & Johnson CEO Joaquin Duato has stated the company will not pursue the obesity market, instead prioritizing its core growth pillar in oncology and addressing challenges like dementia. Duato also indicated that artificial intelligence is expected to significantly accelerate drug discovery and development processes. This strategic focus on oncology and leveraging AI for R&D, while sidestepping the competitive obesity drug market, suggests a continued emphasis on innovation and high-impact therapeutic areas for the healthcare giant.

• 8/2/2026POSITIVE
  This Surgical Robot Could Transform the Operating Room

  Johnson & Johnson has secured FDA approval for its Ottava surgical robot, marking a significant milestone after years of development and substantial investment. This breakthrough positions J&J to potentially disrupt the established surgical robotics market, currently dominated by early entrants. Investors will be watching closely to see if Ottava can gain market share and challenge competitors, potentially driving future revenue growth for the healthcare giant.

• 7/31/2026NEUTRAL
  Wall Street Week | Warsh’s Waiting Game, EU Merger Rules, Robotic Surgeons

  Johnson & Johnson is entering the robotic surgery market, a sector experiencing rapid growth. Despite entering the race years after competitors, the company is banking on a distinct strategy to achieve success. This move signifies J&J's strategic diversification into a high-potential medical technology field, aiming to capture market share against established players. Investors will be watching to see if their unique approach can overcome the initial disadvantage and establish a strong foothold in this competitive landscape.

• 6/17/2026NEUTRAL
  J&J Has No Plans to Enter Obesity Drugs Market, CEO Says

  Johnson & Johnson's CEO, Joaquin Duato, has stated the company has no immediate plans to enter the lucrative obesity drug market. This strategic decision shifts focus towards core areas like oncology, differentiating J&J from competitors actively pursuing weight-loss medications. While rivals Eli Lilly and Novo Nordisk have seen success with their obesity drugs, J&J's stance suggests a preference for its established therapeutic areas. Investors will monitor if this focus yields competitive advantages or if J&J misses out on a significant growth opportunity.

• 4/14/2026POSITIVE
  Inside J&J’s Next Blockbuster Drug

  Johnson & Johnson's CFO, Joseph Wolk, indicated that the company's new psoriasis pill is on track to become a major revenue driver, having already reached 1,500 patients within days of launch. This positive development, coupled with a robust internal pipeline that allows J&J to bypass large, risky acquisitions, supports the company's decision to raise its financial guidance. Investors can anticipate continued long-term double-digit growth, driven by innovative pharmaceutical products and strategic pipeline management.

• 4/9/2026NEUTRAL
  Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

  Johnson & Johnson (JNJ) is set to report its Q1 earnings on April 14th, with analysts forecasting $2.67 per share and $23.6 billion in revenue. The company also received FDA approval for its TECNIS PureSee lens, a positive development for its medical devices segment. While the lens approval offers a potential growth catalyst, the upcoming earnings report carries significant weight. Investors will be closely watching revenue figures and forward guidance to gauge the company's performance and outlook amidst evolving market conditions and healthcare sector dynamics.

• 3/6/2026POSITIVE
  FDA Clears Johnson & Johnson's Multiple Myeloma Combo Drug After Strong Survival Results

  The FDA has approved Johnson & Johnson's combination therapy, Tecvayli with Darzalex Faspro, for multiple myeloma. This approval follows strong Phase 3 survival results, indicating significant patient benefit. The clearance marks a key advancement for J&J in the oncology space, bolstering its innovative treatment portfolio. For investors, the green light for new drugs with promising outcomes can lead to increased future revenue and a higher stock valuation, signaling a robust development pipeline.